ArticleRSC advances2026
Synthesis, molecular modelling, and evaluation of new mono- and bis-isoxazolines as antibacterial agents:
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated computational and biochemical identification of quinoline-8-arylsulfonamides as disruptors of the Skp2-Cks1 protein-protein interaction.Journal of molecular modeling · 2026Article
- Linsitinib: a tyrosine kinase inhibitor with dual host-parasite targeting potential against leishmaniasis.Folia microbiologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to design, synthesize, and evaluate a novel series of isoxazoline-thiosemicarbazone derivatives as potential antibacterial agents, supported by computational investigations. Compounds were synthesized and characterized using
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.